Abstract
Thrombophilia is considered to increase the risk of venous thrombosis (VT) due to hemostasis activation. To determine the level of hemostasis activation in thrombophilic subjects with or without a history of VT, hemostasis activation markers prothrombin fragment 1 and 2 (F1+2), thrombin—antithrombin complex (TAT), and cross-linked fibrin degradation products (D-dimer) were measured in 94 subjects with (patients) and 101 subjects without a history of VT (controls). A total of 34.8% of patients and 14.8% of controls (P = .002) had at least 1 thrombophilic defect (protein C deficiency, activated protein C [APC] resistance, presence of lupus anticoagulants, or prothrombin G20210A polymorphism). The subjects were divided into 4 subgroups: patients with (TF+ patients) and without (TF− patients) thrombophilia, and controls with (TF+ controls) and without (TF− controls) thrombophilia. Hemostasis activation was comparable between all patients and controls (TAT: 2.1 vs 2.6 µg/L; F1+2: 1.0 vs 0.9 nmol/L; D-dimer: 36 vs 37 µg/L, respectively) and between TF+ and TF− patients. However, TF+ controls had a significantly higher prevalence of increased hemostasis activation markers compared with TF− controls (TAT > 4.4 µg/L, 38.4 vs 7.3%; F1+2 > 1.1 nmol/L, 53.8 vs 22.0%; D-dimer > 78 µg/L, 30.7 vs 8.8% of subjects, respectively; all P < .05). After stratification for thrombophilic defects, hemostasis activation was associated with APC resistance in controls and with protein C deficiency in patients. To conclude, thrombophilia was associated with hemostasis activation in controls. We assumed that, in patients, the differences in hemostasis activation between subjects with or without thrombophilia were blurred due to undetermined and unidentified thrombophilic defects.